EPISODE · Jul 23, 2025 · 21 MIN
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
from Decera Clinical Education Oncology Podcast · host James Davis PharmD BCOP, Victoria Nachar PharmD BCOP
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trial Presenters:James Davis, PharmD, BCOPClinical Pharmacy Specialist, Malignant HematologyMUSC Hollings Cancer CenterAssistant ProfessorMUSC College of PharmacyCharleston, South CarolinaVictoria Nachar, PharmD, BCOPClinical Pharmacist Specialist, HematologyUniversity of Michigan Rogel Cancer CenterAnn Arbor, MichiganLink to full program: https://bit.ly/3H2EcSX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP explore the latest key clinical updates on BTK inhibitors in CLL, featuring insights from the randomized phase III FLAIR, SEQUOIA, and BRUIN CLL-321 trials presented at ASCO and EHA 2025. This episode unpacks evolving treatment strategies, MRD-guided approaches, and what these developments mean for oncology professionals.
NOW PLAYING
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m